CLEARWATER, Fla., Sept. 19, 2018 /PRNewswire/ — Acacia Diversified Holdings, Inc. (“Acacia” or the “Company”) (OTCQB symbol: ACCA), an emerging cannabis company, through its wholly owned subsidiaries, MariJ Pharmaceuticals, Inc. (MariJ), Canna-Cures Research and Development Center, Inc. (Canna-Cures), MEDAHUB companies, Inc. (MEDAHUB) and Eufloria Medical of Tennessee, Inc. (Eufloria), focused on the growing and distribution of new and proprietary medicinal hemp products for patients, USDA certified organic mobile processing and handling solutions for its customers, technology solutions for regulators, the expanding physician market and white label manufacturing, is pleased to announce that the company has appointed a new board member, Dr. Richard Paula, MD.
“We are pleased to have such a highly qualified physician join the team as our newest Director for the Board,” said Richard K. Pertile, Acacia’s Chief Executive Officer. Dr. Richard Paula, MD has over 2 decades in the medical field, currently serving as Physician Executive for a major hospital chain. From 2010 – 2014, he served as Vice president and CMIO at Tampa General, and is married with 2 children.
Statements in this press release may be “forward-looking statements” within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as “anticipate”, “believe”, “estimate”, “expect”, “intend” and similar expressions, as they relate to the company or its management, identify forward-looking statements. These statements are based on current expectations, estimates and projections about the company’s business based, in part, on assumptions made by management. These statements are not guarantees of future performance and involve risks, uncertainties and assumptions that are difficult to predict. Therefore, actual outcomes and results may, and probably will, differ materially from what is expressed or forecasted in such forward-looking statements due to numerous factors. Any forward-looking statements speak only as of the date on which they are made, and the Company does not undertake any obligation to update any forward-looking statement to reflect events or circumstances after the date of this release. Information on the Acacia or MariJ Pharmaceuticals websites does not constitute a part of this release.